For the first time, the federal government is proposing cutting the nicotine level in cigarettes so they aren’t so addictive.
U.S. Food and Drug Administration chief Scott Gottlieb directed the agency’s staff Friday to develop new regulations on nicotine. The FDA has had the power since 2009 to regulate nicotine levels, but so far it hasn’t done so.
Stocks of cigarette makers plunged after the announcement.
Gottlieb also said the FDA is giving e-cigarette makers four more years to comply with a review of products already on the market. The agency needs to concentrate on nicotine regulation and not be distracted by the debate on whether e-cigarettes help smokers quit, he said.
“A renewed focus on nicotine can help us to achieve a world where cigarettes no longer addict future generations of our kids,” Gottlieb said in a speech to staff in Silver Spring, Md.
Tar and other substances inhaled through smoking make cigarettes deadly, but the nicotine in tobacco is what makes them addictive. Tobacco use is the leading cause of preventable heart disease, cancer and death in the United States, causing more than 480,000 deaths annually.
Gottlieb said he has asked the FDA’s Center for Tobacco Products to explore whether lowering nicotine levels could create a black market for higher-nicotine products and what role e-cigarettes and other forms of nicotine delivery may play in reducing harm from smoking. Battery-powered e-cigarettes turn liquid nicotine into an inhalable vapor.
Gottlieb also wants new rules to address flavored tobacco products and kids.
U.S. smoking rates have been falling for decades. They dropped from about 17% in 2014 to 15% in 2015 and held about steady at that level last year.
The FDA announcement is great news, said Eric Donny, a University of Pittsburgh researcher who has studied what happens when smokers puff on cigarettes with lower levels of nicotine. Donny and other researchers found that reducing nicotine substantially — by about 90% — leads smokers to be less dependent on cigarettes and smoke fewer of them.
There have been concerns that smokers might react to lower nicotine levels by smoking more cigarettes to compensate. But the research shows that’s not what happens — not if enough nicotine is taken out, Donny said.
“If you just reduce it a little, people might smoke more to make up the difference. They need to reduce it a lot,” said Donny, who said regulators should consider a 95% to 97% reduction.
“Most of the harm associated with smoking is related not to the nicotine but everything else in the smoke. Reducing nicotine doesn’t make a cigarette safe, it just makes it less addictive,” said Donny, director of Pitt’s Center for the Evaluation of Nicotine in Cigarettes.
Additional research is underway to see how often people who smoke lower-nicotine cigarettes switch to e-cigarettes or other, less harmful tobacco products, he said.
Kenneth Warner, a retired University of Michigan public health professor who is a leading authority on smoking and health, said he was pleasantly surprised to learn of the FDA announcement.
“If you can separate the nicotine people are craving from the smoke that’s killing them, then you may be doing something very important,” Warner said.
Matthew Myers, president of Campaign for Tobacco-Free Kids, praised the overall approach, calling it “a bold and comprehensive vision.” But the e-cigarettes delay is “a serious error,” he said.
“This long delay will allow egregious, kid-friendly e-cigarettes and cigars, in flavors like gummy bear, cherry crush and banana smash, to stay on the market with little public health oversight,” Myers said in a statement.
Altria Group, which sells Marlboro and other cigarettes in the U.S., said it would be “fully engaged” in the FDA’s rule-making process. Altria also makes e-cigarettes.
“It’s important to understand that any proposed rule such as a nicotine product standard must be based on science and evidence, must not lead to unintended consequences and must be technically achievable,” the company said in a statement.
Altria shares were down 10.2% at $66.43 around noon Pacific Time. The stock had been down as much as 18.9% shortly after the FDA’s announcement.
1:15 p.m.: This article was updated throughout with quotes and additional details and background information.
This article was originally published at 11 a.m.